Answers are grounded in this paper and cite their sources.
Background: β-cell degeneration and complete insulin insufficiency are hallmarks of Type 1 Diabetes Mellitus (T1DM), a chronic autoimmune illness. Though their clinical significance is yet unknown, immune checkpoints such T cell immunoreceptor with Ig and ITIM domains (TIGIT) may be involved in regulating autoimmunity in type 1 diabetes. Objectives: To investigate serum TIGIT level in Iraqi patients with T1DM and assess their relationship with glycemic status and β-cell function. Methodology: A case-control study was conducted on 150 participants from Baghdad (May 2025- August 2025), including 100 T1DM patients (3–29 years) and 50 healthy controls. Venous blood samples were analyzed for HbA1c, fasting blood sugar (FBS), C-peptide, and TIGIT levels using ELISA. Statistical analysis was performed using SPSS 2019, with P ≤ 0.05 considered significant. Results: Patients showed significantly higher HbA1c (10.47 ± 0.22% vs. 4.81 ± 0.08%, P = 0.0001), FBS (14.95 ± 0.71 vs. 5.20 ± 0.13 mg/dL, P = 0.0001), and TIGIT levels (7.93 ± 0.13 vs. 2.91 ± 0.08 ng/mL, P = 0.0001) compared to controls. C-peptide was markedly reduced in patients (0.0045 ± 0.0003 vs. 1.152 ± 0.065 ng/mL, P = 0.0001). TIGIT levels showed no significant correlation with HbA1c, FBS, or C-peptide. Conclusion: TIGIT is significantly elevated in T1DM patients, independent of glycemic control and β-cell reserve, indicating its potential as an immunological biomarker for disease profiling. Further studies are warranted to explore its prognostic and therapeutic implications.
No takes yet. Share an insight, caveat, or question.
Hadi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: